Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Triethylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentaethylene Glycol SCHEMBL1627452 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Phosphoric Acid SCHEMBL899139 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL816783 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Tetraethylene Glycol SCHEMBL236335 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Hexaethylene Glycol SCHEMBL875412 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL874011 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL854457 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL125344 | 0.97 | TSHR (0.67) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL28090651 | 0.97 | TSHR (0.67) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL8621256 | 0.97 | TSHR (0.67) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238435-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240207430-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12018087-B2 | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject | DYNE THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240197905-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197901-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-12012460-B2 | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide | DYNE THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-12005124-B2 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | DYNE THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240182561-A1 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240173426-A1 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | REGENERON PHARMACEUTICALS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2024107765-A2 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | REGENERON PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-1997043404-A2 | RIBOZYME VARIANTS WITH IMPROVED CATALYTIC ACTIVITY UNDER LOW MAGNESIUM CONDITIONS | HYBRIDON, INC. (US) | 1997-11-20 | — | — | WO | disclosed |
| US-5679554-A | LINKING A CYCLOHEXANEDIOL, A STEROID, A LUPENEDIOL OR ISOSORBIDE TO FLANKING REGIONS OF A RIBOZYME HAVING AN ENDONUCLEOLYTICALLY ABILITY TO CLEAVE RNA; INCREASED NUCLEASE RESISTANCE; HALF-LIVES; ANTISENSE OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| US-5679555-A | ENDONUCLEOLYTICALLY CLEAVING RNA BY A RIBOZYME HAVING FLANKING REGIONS LINKED BY A CYCLOHEXANEDIOL, A STEROID, A LUPENEDIOL OR ISOSORBIDE; INCREASED NUCLEASE RESISTANCE; HALF-LIVES; ANTISENSE OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0791060-A2 | RIBOZYME ANALOGS | HYBRIDON, Inc. (US) | 1997-08-27 | — | — | EP | disclosed |
| US-5650502-A | Ribozyme analogs having rigid non-nucleotidic linkers | HYBRIDON, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| EP-0783570-A1 | FINDERONS AND METHODS OF THEIR PREPARATION AND USE | HYBRIDON, Inc. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5646021-A | CLEAVAGE OF RNA | HYBRIDON, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627055-A | Finderons and methods of their preparation and use | HYBRIDON, INC. (US) | 1997-05-06 | — | — | US | disclosed |
| WO-1996015240-A2 | RIBOZYME ANALOGS | HYBRIDON, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996010080-A1 | FINDERONS AND METHODS OF THEIR PREPARATION AND USE | HYBRIDON, INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018087-B2 | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject | MUSK, MYOF, TFRC | MEN1 4651/4885KMT2A 2797/4885TSHR 110/4885 |
| US-12012460-B2 | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide | MUSK, TFRC, MYOF | MEN1 4769/4885KMT2A 2598/4885TSHR 86/4885 |
| US-12005124-B2 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | UTRN, MUSK, MYOF | MEN1 4745/4885KMT2A 2688/4885TSHR 2597/4885 |
| US-20240197901-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | MUSK, MYOF, MYLK2 | MEN1 3988/4885KMT2A 2558/4885TSHR 1186/4885 |
| US-20240197905-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | UTRN, MUSK, MYOF | MEN1 4745/4885KMT2A 2688/4885TSHR 2597/4885 |
| US-20240182561-A1 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | CACNG1, CACNG3, CACNG2 | MEN1 4182/4885KMT2A 3727/4885TSHR 3745/4885 |
| US-20240207430-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | UTRN, MUSK, MYOF | MEN1 4745/4885KMT2A 2688/4885TSHR 2597/4885 |
| US-20240173426-A1 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | FGFR3, FGFR2, FGFR1 | MEN1 3765/4885KMT2A 2904/4885TSHR 1241/4885 |
| US-20240238435-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | MUSK, MYOF, MYLK2 | MEN1 3988/4885KMT2A 2558/4885TSHR 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.